Geron (NASDAQ:GERN) Shares Up 4.6%

Geron Co. (NASDAQ:GERN - Get Free Report) shares rose 4.6% on Wednesday . The company traded as high as $3.71 and last traded at $3.66. Approximately 2,995,182 shares traded hands during trading, a decline of 73% from the average daily volume of 11,080,196 shares. The stock had previously closed at $3.50.

Analyst Ratings Changes

A number of brokerages have commented on GERN. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 price objective on shares of Geron in a report on Thursday, April 11th. Wedbush restated an "outperform" rating and set a $6.00 price objective on shares of Geron in a research note on Wednesday, April 10th. Finally, The Goldman Sachs Group boosted their price objective on shares of Geron from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Friday, March 15th.

Geron Stock Up 2.3 %

The firm's 50-day moving average price is $2.80 and its 200 day moving average price is $2.27. The firm has a market cap of $1.96 billion, a P/E ratio of -10.85 and a beta of 0.62. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.14.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. During the same period in the prior year, the business posted ($0.10) EPS. The business's revenue for the quarter was down 77.7% compared to the same quarter last year. As a group, research analysts expect that Geron Co. will post -0.34 earnings per share for the current year.

Hedge Funds Weigh In On Geron

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GERN. SG Americas Securities LLC acquired a new stake in shares of Geron in the third quarter worth $40,000. Commonwealth Equity Services LLC increased its holdings in shares of Geron by 20.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 218,297 shares of the biopharmaceutical company's stock valued at $463,000 after purchasing an additional 36,358 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Geron by 19.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 104,023 shares of the biopharmaceutical company's stock worth $221,000 after purchasing an additional 16,992 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Geron by 29.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 73,470 shares of the biopharmaceutical company's stock worth $156,000 after purchasing an additional 16,653 shares during the period. Finally, Chicago Partners Investment Group LLC increased its stake in Geron by 40.2% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 29,866 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 8,557 shares during the period. Institutional investors and hedge funds own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.